PIC Therapeutics is a biotechnology company focused on fundamentally changing how we treat cancer by developing a new generation of therapeutics based on the modulation of RNA translation. PIC's therapeutics target the 'master switch' of cancer signaling pathways, selectively blocking oncogene protein production by modulating the Pre-Initiation Complex (PIC) that drives their mRNA translation. PIC Therapeutics' selective approach has the potential to simultaneously modulate multiple oncogenic drivers leading to a powerful new generation of cancer-treating therapeutics.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 04/15/20 | $5,000,000 | Seed |
Advent Life Sciences Termeer Family Office | undisclosed |
| 10/19/22 | $35,000,000 | Series A |
Advent Life Sciences Harrington Discovery Institute Lumira Ventures OrbiMed Advisors Termeer Family Office | undisclosed |
